氯氮平增效策略。
Clozapine augmentation strategies.
作者信息
Roerig James L
出版信息
Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.
Abstract
Clozapine is established as the gold standard for antipsychotic treatment of patients suffering from treatment-resistant schizophrenia. Over virtually 3 decades, the level of inadequate response to clozapine was found to range from 40% to 60%. A heightened interest developed in the augmentation of clozapine to try to achieve response or maximize partial response. A large variety of drug groups have been investigated. This article focuses on the meta-analyses of these trials to discover reasonable evidence-based approaches to the management of patients not responding to clozapine.
摘要
氯氮平已被确立为治疗难治性精神分裂症患者抗精神病治疗的金标准。在近30年里，发现对氯氮平反应不足的比例在40%至60%之间。人们对增强氯氮平疗效以试图实现有效反应或使部分反应最大化的兴趣日益浓厚。已经对各种各样的药物组进行了研究。本文重点关注这些试验的荟萃分析，以发现合理的循证方法来管理对氯氮平无反应的患者。
相似文献
1
Clozapine augmentation strategies.氯氮平增效策略。
Ment Health Clin. 2019 Nov 27;9(6):336-348. doi: 10.9740/mhc.2019.11.336. eCollection 2019 Nov.
2
Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine.氯氮平治疗部分反应者和/或难治性精神分裂症患者的增效策略。
Expert Opin Pharmacother. 2014 Nov;15(16):2329-45. doi: 10.1517/14656566.2014.956082. Epub 2014 Oct 5.
3
[Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment].[对氯氮平治疗有部分反应的精神分裂症患者的增效策略]
Turk Psikiyatri Derg. 2014 Fall;25(3):201-11.
4
Clozapine resistant schizophrenia: Newer avenues of management.氯氮平难治性精神分裂症：新的治疗途径
World J Psychiatry. 2021 Aug 19;11(8):429-448. doi: 10.5498/wjp.v11.i8.429.
5
Augmentation strategies in clozapine-resistant schizophrenia.氯氮平抵抗性精神分裂症的增效策略
CNS Drugs. 2005;19(10):843-72. doi: 10.2165/00023210-200519100-00004.
6
Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis.氯氮平难治性精神分裂症的增效策略：系统评价和荟萃分析。
Aust N Z J Psychiatry. 2018 Aug;52(8):751-767. doi: 10.1177/0004867418772351. Epub 2018 May 6.
7
Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia.氯氮平与抗精神病药物联用治疗超难治性精神分裂症的增效策略
Clin Neuropharmacol. 2006 Jan-Feb;29(1):28-33. doi: 10.1097/00002826-200601000-00009.
8
Schizophrenia: when clozapine fails.精神分裂症：氯氮平治疗失败时。
Curr Opin Psychiatry. 2015 May;28(3):243-8. doi: 10.1097/YCO.0000000000000159.
9
Clozapine resistance: augmentation strategies.氯氮平耐药：增效策略。
Eur Neuropsychopharmacol. 2012 Mar;22(3):165-82. doi: 10.1016/j.euroneuro.2011.08.005. Epub 2011 Sep 9.
10
ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials.ECT 增强氯氮平治疗氯氮平抵抗性精神分裂症：一项随机对照试验的荟萃分析。
J Psychiatr Res. 2018 Oct;105:23-32. doi: 10.1016/j.jpsychires.2018.08.002. Epub 2018 Aug 2.
引用本文的文献
1
Following the Action of Atypical Antipsychotic Clozapine and Possible Prediction of Treatment Response in Schizophrenia.非典型抗精神病药物氯氮平的作用及精神分裂症治疗反应的可能预测
Life (Basel). 2025 May 22;15(6):830. doi: 10.3390/life15060830.
2
Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis.基于CiteSpace文献计量学分析的难治性精神分裂症（TRS）研究的知识领域与趋势
Front Pharmacol. 2024 Nov 5;15:1478625. doi: 10.3389/fphar.2024.1478625. eCollection 2024.
3
Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients.难治性精神分裂症的免疫炎症特征与认知功能：揭示氯氮平抵抗患者的不同模式
Eur Arch Psychiatry Clin Neurosci. 2024 Aug 28. doi: 10.1007/s00406-024-01885-x.
4
Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia.氯氮平治疗难治性精神分裂症及其联合电休克治疗超难治性精神分裂症
Biomedicines. 2023 Apr 2;11(4):1072. doi: 10.3390/biomedicines11041072.
5
Efficacy of Electroconvulsive Therapy for the Treatment of Movement Disorders: A Literature Review.电休克治疗对运动障碍的疗效：文献综述
Cureus. 2023 Mar 24;15(3):e36634. doi: 10.7759/cureus.36634. eCollection 2023 Mar.
6
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.氨磺必利增效治疗改善氯氮平难治性精神分裂症患者的认知功能和精神病理学：一项 12 周随机、双盲、安慰剂对照试验。
Mil Med Res. 2022 Oct 18;9(1):59. doi: 10.1186/s40779-022-00420-0.
7
A systematic review on the use of clozapine in treatment of tardive dyskinesia and tardive dystonia in patients with psychiatric disorders.系统评价氯氮平治疗精神障碍患者迟发性运动障碍和迟发性肌张力障碍的疗效。
Psychopharmacology (Berl). 2022 Nov;239(11):3393-3420. doi: 10.1007/s00213-022-06241-2. Epub 2022 Sep 30.
8
Clozapine resistant schizophrenia: Newer avenues of management.氯氮平难治性精神分裂症：新的治疗途径
World J Psychiatry. 2021 Aug 19;11(8):429-448. doi: 10.5498/wjp.v11.i8.429.
9
Progress in Schizophrenia Research and Treatment.精神分裂症的研究与治疗进展
Focus (Am Psychiatr Publ). 2020 Oct;18(4):440-442. doi: 10.1176/appi.focus.18310. Epub 2020 Nov 5.
10
Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.使用卡立普多治疗精神分裂症：从临床研究到临床实践。国际专家小组的真实世界经验与建议。
Ann Gen Psychiatry. 2020 Sep 26;19:55. doi: 10.1186/s12991-020-00305-3. eCollection 2020.
本文引用的文献
1
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.抗精神病药联合治疗与单药治疗与成人精神分裂症患者精神科再入院的关联。
JAMA Psychiatry. 2019 May 1;76(5):499-507. doi: 10.1001/jamapsychiatry.2018.4320.
2
Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis.氯氮平治疗抵抗的精神分裂症特定症状领域的辅助第二代抗精神病药：荟萃分析。
J Psychiatr Res. 2019 Jan;108:24-33. doi: 10.1016/j.jpsychires.2018.11.005. Epub 2018 Nov 3.
3
ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials.ECT 增强氯氮平治疗氯氮平抵抗性精神分裂症：一项随机对照试验的荟萃分析。
J Psychiatr Res. 2018 Oct;105:23-32. doi: 10.1016/j.jpsychires.2018.08.002. Epub 2018 Aug 2.
4
Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis.氯氮平难治性精神分裂症的增效策略：系统评价和荟萃分析。
Aust N Z J Psychiatry. 2018 Aug;52(8):751-767. doi: 10.1177/0004867418772351. Epub 2018 May 6.
5
Pharmacological interventions for psychosis in Parkinson's disease patients.帕金森病患者精神病的药物干预。
Expert Opin Pharmacother. 2018 Apr;19(5):499-505. doi: 10.1080/14656566.2018.1445721. Epub 2018 Mar 1.
6
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.治疗帕金森病精神病相关的幻觉和妄想。
Curr Psychiatry Rep. 2018 Jan 27;20(1):3. doi: 10.1007/s11920-018-0869-z.
7
Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis.电休克治疗与抗精神病药物（氯氮平和非氯氮平）联合用于难治性精神分裂症的治疗：一项比较性荟萃分析。
Heliyon. 2017 Nov 3;3(11):e00429. doi: 10.1016/j.heliyon.2017.e00429. eCollection 2017 Nov.
8
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.神经精神药理学治疗药物监测共识指南：2017 年更新版。
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14.
9
Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study.氟伏沙明辅助治疗对氯氮平治疗的精神分裂症患者代谢参数和精神病理学的影响：一项为期 12 周、随机、双盲、安慰剂对照研究。
Schizophr Res. 2018 Mar;193:126-133. doi: 10.1016/j.schres.2017.06.030. Epub 2017 Jul 6.
10
Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.42种联合药物治疗策略联合抗精神病药物单药治疗对精神分裂症的疗效：荟萃分析证据的系统综述与质量评估
JAMA Psychiatry. 2017 Jul 1;74(7):675-684. doi: 10.1001/jamapsychiatry.2017.0624.
Zotero 插件